CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte® SINGAPORE , Sept. 17, 2022 |PRNewswire| -- CellResearch Corporation, a Singapore -based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte ® , a stem cell therapy derived from umbilical cord lining stem cells, with research partners at the University of Colorado , Anschutz Medical Campus and ClinImmune Cell and Gene Therapy. CorLiCyte ® is in development for the treatment of a number of serious conditions, with a first target indication of treating diabetic foot ulcer (DFU). In the study protocol nine patients with chronic DFU were treated with CorLiCyte ® twice weekly for 8 weeks. None of the patients participating in the study experienced any treatment-related adverse events and all subjects saw a reduction in wound size during the treatment period. "These results are encouraging and can be used to support further research with CorLiCyte ® in future studies, with the potential to address unmet medical needs in treatment of patients with chronic DFUs." said Cecilia Low-Wang , the lead investigator at the University of Colorado , Anschutz Medical Campus.